Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Contraception ; 76(2): 111-6, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17656180

RESUMO

OBJECTIVE: The study was conducted to evaluate the effect of Carraguard vaginal gel containing 0.75 mg of levonorgestrel (CARRA/LNG gel) administered in a single dose at different stages of follicle development over subsequent follicle rupture and hormonal levels. METHOD: Randomized, blinded, cross-over study comparing the effects of a single administration of CARRA/LNG gel or Carraguard (CARRA) gel. Twenty-four healthy women were enrolled in two centers. The gels were administered when the follicle had reached diameters of 12-14, 15-17 and > or =18 mm in eight women each. Volunteers were followed for one treatment, one washout cycle and a second treatment cycle. Follicle rupture or nonrupture was assessed by transvaginal ultrasound. Luteinizing hormone, estradiol and progesterone levels were measured daily for 5 days following treatment, and three times per week until menses. RESULTS: No follicular rupture within the 5-day period following administration was observed in 74% and 30% of the CARRA/LNG and CARRA gel treatment cycles, respectively, while ovulation was documented in 4% and 61%, respectively. The overall proportion of cycles with lack of follicular rupture or ovulatory dysfunction (follicle rupture preceded by an inadequate LH surge) was 96% for CARRA/LNG and 39% in the CARRA gel cycles. CONCLUSION: Single vaginal administration of 0.75 mg LNG in CARRA gel in the late follicular phase is effective for interfering with the ovulatory process.


Assuntos
Anticoncepcionais Femininos/administração & dosagem , Levanogestrel/administração & dosagem , Folículo Ovariano/efeitos dos fármacos , Ovulação/efeitos dos fármacos , Administração Intravaginal , Adulto , Anticoncepção Pós-Coito , Anticoncepcionais Femininos/efeitos adversos , Anticoncepcionais Femininos/sangue , Estudos Cross-Over , Feminino , Humanos , Levanogestrel/efeitos adversos , Levanogestrel/sangue , Ciclo Menstrual/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa